Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure

Schneider,Stéfanie  Ingrid dos Reis; Silvello,Daiane; Martinelli,Nidiane  Carla; Garbin,Arthur; Biolo,Andréia; Clausell,Nadine; Andrades,Michael; dos Santos,Kátia   Gonçalves; Rohde,Luís  Eduardo

doi:10.3892/mmr.2018.8428

Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure

Authors:
- Stéfanie Ingrid dos Reis Schneider
- Daiane Silvello
- Nidiane Carla Martinelli
- Arthur Garbin
- Andréia Biolo
- Nadine Clausell
- Michael Andrades
- Kátia Gonçalves dos Santos
- Luís Eduardo Rohde
View Affiliations

Affiliations: Cardiovascular Experimental and Molecular Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035‑903, Brazil
Published online on: January 15, 2018 https://doi.org/10.3892/mmr.2018.8428
Pages: 4736-4746

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs are associated with myocardial damage and heart failure (HF). The present study investigated whether the plasma levels of microRNA (miR)‑21, ‑126 and ‑423‑5p alter according to the (de)compensated state of patients with HF and are associated with all‑cause mortality. In 48 patients with HF admitted to the emergency room for an episode of acute decompensation, blood samples were collected to measure miR and B‑type natriuretic peptide levels within 24 h of hospital admission, at the time of hospital discharge, and a number of weeks post‑discharge (chronic stable compensated state). Levels of miR‑21, miR‑126 and miR‑423‑5p increased between admission and discharge, and decreased following clinical compensation. During follow‑up (up to 48 months), 38 patients (79%) were rehospitalized at least once and 21 patients (44%) succumbed. Patients who had increased levels of miR‑21 and miR‑126 at the time of clinical compensation exhibited better 24‑month survival and remained rehospitalization‑free for a longer period compared with those with low levels. Additionally, patients whose levels of miR‑423‑5p increased between admission and clinical compensation experienced fewer hospital readmissions in the 24 months following the time of clinical compensation compared with those who had decreased levels. It was concluded that the plasma levels of miR‑21, miR‑126 and miR‑423‑5p altered during clinical improvement and were associated with the prognosis of acute decompensated HF.

View Figures

View References

1	Fang YC and Yeh CH: Role of microRNAs in vascular remodeling. Curr Mol Med. 15:684–696. 2015. View Article : Google Scholar : PubMed/NCBI
2	Small EM and Olson EN: Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336–342. 2011. View Article : Google Scholar : PubMed/NCBI
3	Zhou J, Dong X, Zhou Q, Wang H, Qian Y, Tian W, Ma D and Li X: MicroRNA expression profiling of heart tissue during fetal development. Int J Mol Med. 33:1250–1260. 2014. View Article : Google Scholar : PubMed/NCBI
4	Papageorgiou N, Tslamandris S, Giolis A and Tousoulis D: MicroRNAs in cardiovascular disease: Perspectives and reality. Cardiol Rev. 24:110–118. 2016. View Article : Google Scholar : PubMed/NCBI
5	Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M and Holvoet P: Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc Res. 111:322–337. 2016. View Article : Google Scholar : PubMed/NCBI
6	Romaine SP, Tomaszewski M, Condorelli G and Samani NJ: MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart. 101:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
7	Cakmak HA, Coskunpinar E, Ikitimur B, Barman HA, Karadag B, Tiryakioglu NO, Kahraman K and Vural VA: The prognostic value of circulating microRNAs in heart failure: Preliminary results from a genome-wide expression study. J Cardiovasc Med (Hagestown). 16:431–437. 2015. View Article : Google Scholar
8	Qiang L, Hong L, Ningfu W, Huaihong C and Jing W: Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol. 168:2082–2088. 2013. View Article : Google Scholar : PubMed/NCBI
9	Fukushima Y, Nakanishi M, Nonogi H, Goto Y and Iwai N: Assessment of plasma miRNAs in congestive heart failure. Circ J. 75:336–340. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bruno N, Ter Maaten JM, Ovchinnikova ES, Vegter EL, Valente MA, van der Meer P, de Boer RA, van der Harst P, Schmitter D, Metra M, et al: MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol. 203:564–569. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ovchinnikova ES, Schmitter D, Vegter EL, Ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, et al: Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 18:414–423. 2016. View Article : Google Scholar : PubMed/NCBI
12	Seronde MF, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB, Vodovar N, Sadoune M, Samuel JL, Thum T, et al: Circulating microRNAs and outcome in patients with acute heart failure. PLoS One. 10:e01422372015. View Article : Google Scholar : PubMed/NCBI
13	Xiao J, Gao R, Bei Y, Zhou Q, Zhou Y, Zhang H, Jin M, Wei S, Wang K, Xu X, et al: Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem. 41:865–874. 2017. View Article : Google Scholar : PubMed/NCBI
14	Fan KL, Zhang HF, Shen J, Zhang Q and Li XL: Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J. 65:12–16. 2013. View Article : Google Scholar : PubMed/NCBI
15	Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS and Amir O: Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 14:147–154. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res. 106:1035–1039. 2010. View Article : Google Scholar : PubMed/NCBI
17	Biolo A, Fisch M, Balog J, Chao T, Schulze PC, Ooi H, Siwik D and Colucci WS: Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail. 3:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S and Takatsu Y: Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 103:369–374. 2001. View Article : Google Scholar : PubMed/NCBI
19	Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M, Siwik D and Colucci WS: Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Cardiac Fail. 17:1004–1011. 2011. View Article : Google Scholar
20	DeAguero JL, McKown EN, Zhang L, Keirsey J, Fischer EG, Samedi VG, Canan BD, Kilic A, Janssen PM and Delfín DA: Altered protein levels in the isolated extracellular matrix of failing human hearts with dilated cardiomyopathy. Cardiovasc Pathol. 26:12–20. 2017. View Article : Google Scholar : PubMed/NCBI
21	Thomé JG, Mendoza MR, Cheuiche AV, La Porta VL, Silvello D, Dos Santos KG, Andrades ME, Clausell N, Rohde LE and Biolo A: Circulating microRNAs in obese and lean heart failure patients: A case-control study with computational target prediction analysis. Gene. 574:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, Nonogi H, Ma X, Weng H, Hirokawa G, et al: MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull. 36:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wang J, Liew OW, Richards AM and Chen YT: Overview of microRNAs in cardiac hypertrophy, fibrosis, and apoptosis. Int J Mol Sci. 17:E7492016. View Article : Google Scholar : PubMed/NCBI
25	Liu R-H, Ning B, Ma X-E, Gong WM and Jia TH: Regulatory roles of microRNA-21 in fibrosis through interaction with diverse pathways (Review). Mol Med Rep. 13:2359–2366. 2016. View Article : Google Scholar : PubMed/NCBI
26	Abdellatif M: Differential expression of microRNAs in different disease states. Circ Res. 110:638–650. 2012. View Article : Google Scholar : PubMed/NCBI
27	Topkara VK and Mann DL: Clinical applications of miRNAs in cardiac remodeling and heart failure. Per Med. 7:531–548. 2010. View Article : Google Scholar : PubMed/NCBI
28	McManus DD, Tanriverdi K, Lin H, Esa N, Kinno M, Mandapati D, Tam S, Okike ON, Ellinor PT, Keaney JF Jr, et al: Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm. 12:3–10. 2015. View Article : Google Scholar : PubMed/NCBI
29	Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG and van Rooij E: Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail. 15:650–659. 2013. View Article : Google Scholar : PubMed/NCBI
30	Li Q, Yu Q, Na R and Liu B: MiR-423-5p inhibits human cardiomyoblast proliferation and induces cell apoptosis by targeting Gab 1. Int J Clin Exp Pathol. 9:8953–8962. 2016.
31	Luo P, He T, Jiang R and Li G: MicroRNA-423-5p targets O-GlcNAc transferase to induce apoptosis in cardiomyocytes. Mol Med Rep. 12:1163–1168. 2015. View Article : Google Scholar : PubMed/NCBI
32	Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, Spazzafumo L, Lisa R, La Sala L, Galeazzi R, et al: Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol. 167:531–536. 2013. View Article : Google Scholar : PubMed/NCBI
33	Goldraich LA, Martinelli NC, Matte U, Cohen C, Andrades M, Pimentel M, Biolo A, Clausell N and Rohde LE: Transcoronary gradient of plasma microRNA 423–5p in heart failure: Evidence of altered myocardial expression. Biomarkers. 19:135–141. 2014. View Article : Google Scholar : PubMed/NCBI
34	Vegter EL, van der Meer P, de Windt LJ, Pinto YM and Voors AA: MicroRNAs in heart failure: From biomarker to target for therapy. Eur J Heart Fail. 18:457–468. 2016. View Article : Google Scholar : PubMed/NCBI
35	Viereck J, Bang C, Foinquinos A and Thum T: Regulatory RNAs and paracrine networks in the heart. Cardiovasc Res. 102:290–301. 2014. View Article : Google Scholar : PubMed/NCBI
36	Caroli A, Cardillo MT, Galea R and Biasucci LML: Potential therapeutic role of microRNAs in ischemic heart disease. J Cardiol. 61:315–320. 2013. View Article : Google Scholar : PubMed/NCBI